Newsfeeds Archive - Page 18 of 194

1 minute read

September 18, 6:08 AM

Flora Growth Corp. (NASDAQ:FLGC) ("Flora" or the "Company"), a global consumer-packaged goods leader and pharmaceutical distributor serving all 50 states and 28 countries with 20,000+ points of

FLGC

1 minute read

News

Advanced Health Intelligence Signed Collaboration Agreement with Bin Farhood International Business Management Group

By Charles Gross

September 11, 7:22 PM

Advanced Health Intelligence Ltd (NASDAQ:AHI) (“AHI” or the “Company”) is pleased to inform shareholders that the Company

AHI

1 minute read

News

Moderna and Immatics Announce Strategic Multi-Platform Collaboration to Develop Innovative Oncology Therapeutics

By Charles Gross

September 11, 6:40 AM

Moderna, Inc. (NASDAQ:MRNA, &ldquo, Moderna&rdquo, )) and Immatics N.V. (NASDAQ:IMTX, &ldquo, Immatics&rdquo, )), a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecting

IMTX

1 minute read

Events
News

Zevra Therapeutics Announced Late Saturday, Presentation Of Full Data Set On The Cardiovascular Safety And Pharmacokinetics Of SDX, The Sole API In KP1077, In Healthy Volunteers At Psych Congress 2023

By Charles Gross

September 10, 10:38 AM

Zevra Therapeutics, Inc. (NASDAQ:ZVRA) (Zevra, or the Company), a rare disease therapeutics company, today announced a poster presentation featuring study data that underscores the cardiovascular safety profile of

ZVRA

1 minute read

News

Supernus Late Saturday, Announced New Qelbree Data Showing Improvement In ADHD Symptoms

By Charles Gross

September 10, 10:37 AM

Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, announces the presentation of two

SUPN

1 minute read

Events
News

Mirati Late Saturday, Announced Two-Year Follow-Up Data from KRYSTAL-1 Study Demonstrating Durable Response And Long-Term Overall Survival At 2023 World Conference on Lung Cancer

By Charles Gross

September 10, 10:35 AM

Mirati Therapeutics, Inc. (NASDAQ:MRTX), a commercial stage research and development, biotechnology company, today presented two-year follow-up data from a pooled analysis of the Phase 1/1b Cohort and

MRTX

1 minute read

Events
News

Gilead Earlier Announced Phase 2 Evoke-02 Study Of Trodelvy (Sacituzumab Govitecan-hziy) In Combination With Keytruda (Pembrolizumab) Demonstrates Clinical Activity In First-line Metastatic Non-small Cell Lung Cancer

By Charles Gross

September 10, 10:33 AM

Gilead Sciences, Inc. (NASDAQ:GILD) today announced promising early data from the global, open-label, Phase 2 EVOKE-02 study evaluating Trodelvy® (sacituzumab govitecan-hziy) in combination with Merck’s

GILD

1 minute read

Events
News

Amgen Presented New Lumakras (Sotorasib) Plus Chemotherapy Data In First-line Kras G12c NASLC At WCLC; Said Data Demonstrated A Confirmed Objective Response Rate Of 65%

By Charles Gross

September 10, 10:30 AM

Amgen (NASDAQ:AMGN) today announced exciting data from a study arm of the CodeBreaK 101 clinical trial, a Phase 1b study evaluating LUMAKRAS® (sotorasib) with carboplatin and pemetrexed in adult

AMGN

1 minute read

Events
News

Mineralys Therapeutics Announced Target-htn Successfully Met Its Primary Endpoint; Key Secondary Endpoint Results Demonstrated A Change In Diastolic Aobp Of -7.1 Mmhg With 50mg

By Charles Gross

September 10, 10:27 AM

Mineralys Therapeutics, Inc. (NASDAQ:MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease and other diseases driven by abnormally elevated

MLYS

1 minute read

News

Mineralys Therapeutics Announced JAMA Publication Of Full Target-HTN Phase 2 Trial Results for Lorundrostat In Uncontrolled and Treatment-Resistant Hypertension

By Charles Gross

September 10, 10:24 AM

MLYS